clinical trial · NCT06112327
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
Verve Therapeutics, Inc.·—·enrolling by invitation·n = 116
Atherosclerotic Cardiovascular DiseaseHeterozygous Familial HypercholesterolemiaHypercholesterolemia
brief summary
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.
started
Jun 9, 2024
primary completion
Oct 1, 2039
completion
Oct 1, 2039
last updated
Apr 8, 2026
official title
Long-term Follow-up Study of Investigational Gene-editing Therapies in Participants With or at High Risk for Cardiovascular Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol